Ayurcann Holdings Corp. (AYUR) AI Stock Analysis

• Market Cap: C$973.52K
• Dividend Yield: N/A
• Average Volume (3M): 59.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 15.95%
• EPS Growth: -1.81%
• Country: CA
• Employees: N/A
• Sector: N/A
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 194,703,860
• 10 Day Avg. Volume: 17,939
• 30 Day Avg. Volume: 59,984
• PEG Ratio: 0.07
• Price to Book (P/B): -1.65
• Price to Sales (P/S): 0.16
• P/FCF Ratio: 2.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: C$0.01 ▼(-30.00% Downside)

The score is driven primarily by weak financial health—negative equity, high leverage, and ongoing losses—despite strong revenue growth. Technical indicators also remain bearish with price below major moving averages and a negative MACD. Valuation is constrained by negative earnings and no dividend data.

Ayurcann Holdings Corp. Business Overview & Revenue Model

Company Description

Ayurcann Holdings Corp. (AYUR) is a Canadian company specializing in the production and distribution of cannabis-derived products, focusing on innovative formulations that cater to both the medical and recreational markets. The company operates primarily in the cannabis sector, offering a range of products including oils, capsules, and edibles, with an emphasis on quality and sustainability. Ayurcann is committed to leveraging its proprietary extraction technology and product development capabilities to meet the evolving needs of consumers in the burgeoning cannabis industry.

How the Company Makes Money

Ayurcann Holdings Corp. generates revenue through several key streams, primarily from the sale of its cannabis products, which include oils, capsules, and edibles. The company benefits from its proprietary extraction technologies, allowing it to produce high-quality cannabis extracts that can be sold to other businesses or used in its own product lines. Additionally, Ayurcann may engage in partnerships with licensed producers and retailers, creating collaborative opportunities that enhance distribution and market reach. The company also explores potential joint ventures and agreements with other players in the cannabis sector, which can provide further revenue opportunities and a broadened customer base.

Ayurcann Holdings Corp. Financial Statement Overview

Summary

Strong TTM revenue growth (+55.3%) is outweighed by weak profitability (negative EBIT and net margins) and balance-sheet stress (negative equity and very high leverage), with cash flow also pressured (free cash flow down 72.4% TTM).

Income Statement

Ayurcann Holdings Corp. shows a mixed performance in its income statement. The company has achieved significant revenue growth of 55.3% in the TTM, indicating strong sales momentum. However, profitability remains a concern with negative net profit and EBIT margins, reflecting ongoing operational challenges. The gross profit margin is moderate at 36.7%, but the negative net profit margin of -12.5% highlights the need for cost control and efficiency improvements.

Balance Sheet

The balance sheet reveals financial instability, with a negative stockholders' equity and a high debt-to-equity ratio of -7.77, indicating excessive leverage. The return on equity is also negative, suggesting that the company is not generating sufficient returns on its equity base. The equity ratio is concerning, pointing to potential solvency issues.

Cash Flow

Cash flow analysis shows a decline in free cash flow growth by 72.4% in the TTM, which is a significant drawback. The operating cash flow to net income ratio is negative, indicating that the company is not generating enough cash from its operations to cover its net losses. However, the free cash flow to net income ratio is close to 1, suggesting some level of cash flow stability relative to net income.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Ayurcann Holdings Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AYUR, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 39.93 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AYUR.

Ayurcann Holdings Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
PCLO	44 Neutral	C$13.85M	-2.23	―	―	15.64%	58.47%
LOBE	44 Neutral	C$16.17M	-2.14	―	―	-100.00%	-8.70%
SE	43 Neutral	C$6.59M	-3.63	―	―	-100.00%	-192.62%
MVMD	42 Neutral	C$5.29M	-0.47	-148.48%	―	-46.59%	8.26%
AYUR	40 Underperform	C$973.52K	-0.67	-271.33%	―	15.95%	-1.81%
RVV	40 Underperform	C$4.19M	-0.39	-664.21%	―	―	-80.42%

Ayurcann Holdings Corp. Corporate Events

Ayurcann Seeks CCAA Creditor Protection and Launches Court‑Supervised Sale Process

Ayurcann Holdings Corp. and its subsidiary have obtained creditor protection under the Companies’ Creditors Arrangement Act, with Alvarez & Marsal Canada Inc. appointed as monitor, in a move the board says is in the best interests of the company and its stakeholders. The court order provides an initial 10‑day stay of creditor claims while Ayurcann pursues restructuring options and seeks approval to launch a court‑supervised sale process for its business and assets, supported by planned debtor‑in‑possession financing. Operations are expected to continue without interruption during the proceedings, but trading in Ayurcann’s shares on the Canadian Securities Exchange may be halted and could ultimately lead to suspension or delisting, underscoring the financial strain on the company and the uncertainty facing shareholders and creditors as the restructuring unfolds.

The most recent analyst rating on (TSE:AYUR) stock is a Hold with a C$0.01 price target. To see the full list of analyst forecasts on Ayurcann Holdings Corp. stock, see the TSE:AYUR Stock Forecast page.

Ayurcann Holdings Corp. Reports Strong Q1 2026 Sales and Market Expansion

Ayurcann Holdings Corp. reported Q1 2026 sales of $14,638,697, maintaining a strong presence in the Canadian cannabis market. The company is recognized as a top vape producer in Ontario, with a 5% share of the national vape market. Despite a decrease in gross profit margin from 40% to 26% compared to the previous year, Ayurcann continues to expand its product offerings and retail presence, launching 30 new stock keeping units in the past six months. This strategic growth in product categories like vapes, pre-rolls, and concentrates positions Ayurcann as a trusted national supplier, enhancing its market leadership and operational efficiency.